<?xml version="1.0" encoding="UTF-8"?>
<ref id="pone.0163945.ref011">
 <label>11</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Poynard</surname>
   <given-names>T</given-names>
  </name>, 
  <name>
   <surname>Marcellin</surname>
   <given-names>P</given-names>
  </name>, 
  <name>
   <surname>Lee</surname>
   <given-names>SS</given-names>
  </name>, 
  <name>
   <surname>Niederau</surname>
   <given-names>C</given-names>
  </name>, 
  <name>
   <surname>Minuk</surname>
   <given-names>GS</given-names>
  </name>, 
  <name>
   <surname>Ideo</surname>
   <given-names>G</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)</article-title>. 
  <source>Lancet</source>. 
  <year>1998</year>;
  <volume>352</volume>(
  <issue>9138</issue>):
  <fpage>1426</fpage>â€“
  <lpage>32</lpage>. .
  <?supplied-pmid 9807989?>
  <pub-id pub-id-type="pmid">9807989</pub-id>
 </mixed-citation>
</ref>
